Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects

Clinical Trial ID NCT01252641

PubWeight™ 65.63‹?›

🔗 Visit the page for NCT01252641

Top papers

Rank Title Journal Year PubWeight™‹?›
1 ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol 2013 11.58
2 High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nat Biotechnol 2013 8.40
3 Revealing off-target cleavage specificities of zinc-finger nucleases by in vitro selection. Nat Methods 2011 6.90
4 Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. Nat Commun 2015 2.56
5 Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet 2013 2.11
6 Targeted gene addition to a predetermined site in the human genome using a ZFN-based nicking enzyme. Genome Res 2012 2.02
7 Advances in targeted genome editing. Curr Opin Chem Biol 2012 1.97
8 Prospects for treatment of latent HIV. Clin Pharmacol Ther 2012 1.91
9 Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases. PLoS Pathog 2011 1.50
10 HIV-1 transcription and latency: an update. Retrovirology 2013 1.49
11 Repurposing CRISPR/Cas9 for in situ functional assays. Genes Dev 2013 1.41
12 Cell-penetrating peptide-mediated delivery of TALEN proteins via bioconjugation for genome engineering. PLoS One 2014 1.24
13 Newer gene editing technologies toward HIV gene therapy. Viruses 2013 1.07
14 Novel cell and gene therapies for HIV. Cold Spring Harb Perspect Med 2012 1.07
15 T-cell therapies for HIV. Immunotherapy 2013 0.99
16 Analysis of an artificial zinc finger epigenetic modulator: widespread binding but limited regulation. Nucleic Acids Res 2014 0.95
17 Creating genetic resistance to HIV. Curr Opin Immunol 2012 0.93
18 Host Factors and HIV-1 Replication: Clinical Evidence and Potential Therapeutic Approaches. Front Immunol 2013 0.92
19 A cure for AIDS: a matter of timing? Retrovirology 2013 0.92
20 Targeted gene therapies: tools, applications, optimization. Crit Rev Biochem Mol Biol 2012 0.91
21 HIV-1 latency: an update of molecular mechanisms and therapeutic strategies. Viruses 2014 0.89
22 Practical considerations in gene therapy for HIV cure. Curr HIV/AIDS Rep 2014 0.88
23 Emerging gene editing strategies for Duchenne muscular dystrophy targeting stem cells. Front Physiol 2014 0.86
24 Beyond the antigen receptor: editing the genome of T-cells for cancer adoptive cellular therapies. Front Immunol 2013 0.86
25 Selection-independent generation of gene knockout mouse embryonic stem cells using zinc-finger nucleases. PLoS One 2011 0.85
26 CD4 T-cell immunotherapy for chronic viral infections and cancer. Immunotherapy 2013 0.85
27 HIV-1 functional cure: will the dream come true? BMC Med 2015 0.84
28 State-of-the-art human gene therapy: part II. Gene therapy strategies and clinical applications. Discov Med 2014 0.84
29 Engineering T Cells to Functionally Cure HIV-1 Infection. Mol Ther 2015 0.81
30 Gene therapy strategies for HIV/AIDS: preclinical modeling in humanized mice. Viruses 2013 0.80
31 Cell and gene therapy strategies to eradicate HIV reservoirs. Curr Opin HIV AIDS 2016 0.80
32 Zinc Finger Nucleases: Tailor-made for Gene Therapy. Drugs Future 2012 0.79
33 Genetic rearrangements of variable di-residue (RVD)-containing repeat arrays in a baculoviral TALEN system. Mol Ther Methods Clin Dev 2014 0.79
34 The clinical applications of genome editing in HIV. Blood 2016 0.79
35 Progress toward curing HIV infection with hematopoietic cell transplantation. Stem Cells Cloning 2015 0.78
36 Stem cell-based therapies for HIV/AIDS. Adv Drug Deliv Rev 2016 0.77
37 Controlling HIV-1: Non-Coding RNA Gene Therapy Approaches to a Functional Cure. Front Immunol 2015 0.76
38 TALENs targeting HBV: designer endonuclease therapies for viral infections. Mol Ther 2013 0.76
39 In Vivo Delivery Systems for Therapeutic Genome Editing. Int J Mol Sci 2016 0.75
40 Gene therapy's out-of-body experience. Nat Biotechnol 2016 0.75
41 T-cell therapies for HIV: Preclinical successes and current clinical strategies. Cytotherapy 2016 0.75
Next 100